XNAS · Healthcare · Biotechnology
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | -0.11 | -0.13 | -18.18% | $0 | ❌ Miss | +2.60% | +8.23% | — |
| 2026-04-01 | Q4 2025 | -0.13 | -0.13 | +0.00% | $0 | ➖ Inline | +1.68% | +11.73% | +43.83% |
| 2025-11-14 |
| Q3 2025 |
| -0.15 |
| -0.14 |
| +6.67% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2024-11-14 | Q4 2024 | — | -1.37 | — | $0 | — | -4.08% | -31.63% | -15.51% |
Showing last 4 quarters.